APS — Aptose Biosciences Share Price
0.000.00%
Last trade - 00:00- CA$7.78m
- CA$13.14m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -463.25% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aptose Biosciences Inc. is a clinical-stage biotechnology company engaged in developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. Its lead clinical-stage compound Tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
Directors
- William Rice CHM (62)
- Jotin Marango CFO (42)
- Rafael Bejar SVP (49)
- Janet Clennett VFN
- Roger Davies VOP
- Robert Killion VPR
- George Melko VPR
- Denis Burger LED (77)
- Carol Ashe IND (63)
- Caroline Loewy IND (54)
- Erich Platzer IND (70)
- Mark Vincent IND (68)
- Warren Whitehead IND (69)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 1st, 2006
- Public Since
- June 4th, 1993
- No. of Shareholders
- 8
- No. of Employees
- 13
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 2,552,429
- Address
- 251 Consumers Rd Suite 1105, NORTH YORK, M2J 4R3
- Web
- https://aptose.com/
- Phone
- +1 6474799828
- Auditors
- KPMG LLP
Upcoming Events for APS
Q1 2025 Aptose Biosciences Inc Earnings Release
Aptose Biosciences Inc Annual Shareholders Meeting
Aptose Biosciences Inc Extraordinary Shareholders Meeting
Aptose Biosciences Inc Annual Shareholders Meeting
Q2 2025 Aptose Biosciences Inc Earnings Release
Similar to APS
Aurora Cannabis
Toronto Stock Exchange
Auxly Cannabis
Toronto Stock Exchange
Bausch Health Companies
Toronto Stock Exchange
Canopy Growth
Toronto Stock Exchange
Charlotte's Web Holdings
Toronto Stock Exchange
FAQ
What is the Aptose Biosciences share price?
As of Today at 19:18 UTC, shares in Aptose Biosciences are trading at CA$2.90. This share price information is delayed by 15 minutes.
How has the Aptose Biosciences share price performed this year?
Shares in Aptose Biosciences last closed at CA$2.90 and the price had moved by -94.03% over the past 365 days. In terms of relative price strength the Aptose Biosciences share price has underperformed the Toronto Stock Exchange 300 Composite Index by -94.69% over the past year.
What are the analyst and broker recommendations for Aptose Biosciences?
The overall consensus recommendation for Aptose Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aptose Biosciences dividend yield?
Aptose Biosciences does not currently pay a dividend.
Does Aptose Biosciences pay a dividend?
Aptose Biosciences does not currently pay a dividend.
When does Aptose Biosciences next pay dividends?
Aptose Biosciences does not currently pay a dividend.
How do I buy Aptose Biosciences shares?
To buy shares in Aptose Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aptose Biosciences?
As of the previous close price of CA$2.90, shares in Aptose Biosciences had a market capitalisation of CA$7.78m.
Where are Aptose Biosciences shares listed?
Here are the trading details for Aptose Biosciences:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: APS
What kind of share is Aptose Biosciences?
Based on an overall assessment of its quality, value and momentum Aptose Biosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aptose Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Aptose Biosciences is CA$17.85. That is 515.39% above the last closing price of CA$2.90.
Analysts covering Aptose Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$9.37 for the next financial year.
Find out moreWhat is the trend in the Aptose Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aptose Biosciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -81.52%.
As of the last closing price of CA$2.90, shares in Aptose Biosciences were trading -76.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aptose Biosciences PE Ratio?
The Aptose Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$2.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aptose Biosciences?
Aptose Biosciences' management team is headed by:
- William Rice - CHM
- Jotin Marango - CFO
- Rafael Bejar - SVP
- Janet Clennett - VFN
- Roger Davies - VOP
- Robert Killion - VPR
- George Melko - VPR
- Denis Burger - LED
- Carol Ashe - IND
- Caroline Loewy - IND
- Erich Platzer - IND
- Mark Vincent - IND
- Warren Whitehead - IND